



ASX ANNOUNCEMENT

6 January 2023

## Working Capital Loan Facility

[CardieX Limited](#) (ASX: CDX) (CardieX, the Company) is pleased to advise that its wholly owned subsidiary Atcor Medical Pty Ltd (the “Borrower”), has entered into a short-term working capital loan facility (‘New Loan Facility’) for up to \$880,000.

The New Loan Facility was facilitated over the course of December by Mitchell Asset Management Pty Ltd (‘MAM’), the same lender who currently provides the Company with related commercial financing under the Company’s current R&D Loan Facility.

MAM has advanced the New Loan Facility to the Company on the basis of current project and working capital requirements under previously announced product and development expansion initiatives.

The New Loan Facility has a minimum interest term of 6 months from the date of the first advance, and a maturity/Termination date of 30 October 2023 which has been timed to coincide with key corporate initiatives being led by the Group.

Key terms of the facility are:

<b>Establishment Fee</b>	\$NIL
<b>Legal Costs of the Lender</b>	\$950
<b>Facility Limit</b>	\$880,000
<b>Interest Rate</b>	16% p.a
<b>Interest Period</b>	Monthly
<b>Security</b>	General security, as is the case for existing R&D Loan Facility

The Company is pleased to have established a commercial working capital facility and sees this and similar forms of debt facilities as a relevant element of its working capital strategy as it matures its current product development initiatives into new business units.

**- ENDS -**

***Approved by the Board of Directors and Released by Jarrod White, Director.***

**For more information, please contact:**

**Investor Relations:** Rod Hinchcliffe  
rod.hinchcliffe@mcpartners.com.au

**Media Relations:** Melissa Hamilton  
melissa.hamilton@mcpartners.com.au

**Investor Relations – USA:** Matt Selinger Managing Director, Integrous Communications  
mselinger@integcom.com

**About CardieX:**

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other arterial health disorders. The company's ATCOR division is the world leader in specialist medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the CONNEQT brand, the company develops wearables, digital solutions, and devices for remote patient monitoring, decentralized clinical trials, and home health. CardieX is listed on the Australian Stock Exchange (ASX:CDX).